1. Home
  2. ABUS vs ALOY Comparison

ABUS vs ALOY Comparison

Compare ABUS & ALOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.35

Market Cap

836.0M

Sector

Health Care

ML Signal

HOLD

Logo REalloys Inc. Common Stock

ALOY

REalloys Inc. Common Stock

BUY

Current Price

$7.16

Market Cap

862.3M

Sector

N/A

ML Signal

BUY

Company Overview

Basic Information
Metric
ABUS
ALOY
Founded
2005
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
836.0M
862.3M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
ABUS
ALOY
Price
$4.35
$7.16
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $17.00
AVG Volume (30 Days)
★ 6.3M
1.7M
Earning Date
11-12-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 55.26
N/A
EPS
★ 0.84
N/A
Revenue
★ $14,083,000.00
$692,803.00
Revenue This Year
$1,208.75
$258.37
Revenue Next Year
N/A
$926.02
P/E Ratio
$4.98
★ N/A
Revenue Growth
★ 128.21
N/A
52 Week Low
$3.50
$5.91
52 Week High
$5.45
$26.90

Technical Indicators

Market Signals
Indicator
ABUS
ALOY
Relative Strength Index (RSI) 35.56 36.97
Support Level $4.17 $6.83
Resistance Level $4.57 $9.42
Average True Range (ATR) 0.18 0.42
MACD -0.02 -0.02
Stochastic Oscillator 15.43 37.24

Price Performance

Historical Comparison
ABUS
ALOY

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About ALOY REalloys Inc. Common Stock

REalloys Inc is a development-stage company building a North American integrated rare earth to high-performance neodymium iron boron (NdFeB) magnet materials and magnet supply chain focused on meeting the demands of the protected markets of the United States, which includes the U.S. National Defense Stockpiles (NDS), Defense Industrial Base (DIB), Nuclear Industrial Base (NIB), robotics, electric aviation, and critical infrastructure industries. The company operates in a single, integrated rare-earth development and supply chain enterprise focused on building a North American mine-to-magnet supply chain for U.S. Protected Markets.

Share on Social Networks: